

Corporate Action Notice

December 1, 2016

Rights Offering

Nabriva Therapeutics

DR CUSIP: 62957M104

DR ISIN: US62957M1045

DR Ticker Symbol: NBRV

Ratio (DRs: Underlying Shares): 10:1

Nabriva Therapeutics AG (Nabriva), an Austrian stock corporation, announced the terms for its rights offering. Holders of Nabriva American Depositary Shares ("ADSs") (CUSIP# 62957M104) as of 5:00 pm (New York City time) on November 29, 2016 will receive non-transferable ADS subscription rights to purchase new ADSs.

The details of the offer are as follows:

ADS Rights Distribution Ratio: 0.276 ADS Rights for every one (1) Nabriva ADS held on the ADS Record Date. Each ADS Right will allow the holder to subscribe to one (1) new ADS. Each ADS is equal to one tenth (1/10th) of a common share. Fractional ADS rights will not be issued, and ADS right entitlements will be reduced to the next smaller whole number of ADS rights.

Estimated ADS Subscription Payment: To validly subscribe for new ADSs, holders of ADSs will need to pay to the ADS rights agent \$4.68 for each new ADS subscribed for. This payment represents the U.S. dollar equivalent of €4.014 per ADS (which is estimated at \$4.25 per ADS based on a euro-to-U.S. dollar exchange rate of €1.00 to \$1.0588) plus 10% of the estimated ADS subscription price to account for currency conversion expenses, an ADS issuance fee of the depositary of \$0.05 per new ADS and potential fluctuations in the exchange rate between the euro and the U.S. dollar.

On or about December 13, 2016, the ADS rights agent will determine the actual U.S. dollar ADS subscription price by converting the euro subscription price into U.S. dollars at an exchange rate assigned by it on that date.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis

Richard J Maehr

+ 1 212 815 2267

adrdesk@bnymellon.com

LONDON

Jacek Jankowski

Vice President

+ 44 207 163 7427

jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON

- ADS Record date: **November 29, 2016.**
- The ADS exercise period is November 30, 2016 until December 12, 2016.
- ADS Rights expiration date is 5:00 p.m. New York time on December 12, 2016.
- The ADS rights are * NOT transferable.
- Guarantee Period: * NOT applicable.
- The exercise of ADS rights is irrevocable and may not be cancelled or modified
- Unexercised ADS rights will expire worthless.

Information Agent: Georgeson, LLC: phone number (866) 278-8941 (U.S. toll free) and email: Nabriva@georgeson.com.

The Rights Offering is being made pursuant to the Company's effective shelf registration statement on Form F-3 on file with the U.S. Securities and Exchange Commission (the "SEC"), including the base prospectus, dated November 9, 2016, included therein and a prospectus supplement, dated November 29, 2016, thereto (collectively, the "Prospectus"). The Prospectus and a form letter with subscription instructions for the Rights Offering is available by contacting the information agent, Georgeson LLC, or by visiting the Company's website for the Rights Offering at <http://info.nabriva.com/RightsOffering/Documents.html>. The Prospectus and form letter are also available by visiting the EDGAR system of the SEC at its website at www.sec.gov/edgar.shtml.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis
Richard J Maehr
+ 1 212 815 2267
adrdesk@bnymellon.com

LONDON

Jacek Jankowski
Vice President
+ 44 207 163 7427
jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON